Quarterly report pursuant to Section 13 or 15(d)

REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)

v3.23.3
REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)
9 Months Ended
Sep. 30, 2023
REVENUES FROM CONTRACTS WITH CUSTOMERS  
Schedule of disaggregation of net revenues

Three-Month Periods Ended September 30, 

Nine-Month Periods Ended September 30, 

($ in thousands)

    

2023

    

2022

    

2023

    

2022

Qbrexza®

$

5,865

$

6,265

$

18,038

$

19,752

Accutane®

 

4,882

 

4,121

 

15,109

 

14,228

Amzeeq®

2,336

1,161

4,904

5,892

Zilxi®

681

554

1,567

1,851

Targadox®

929

1,168

2,386

6,558

Exelderm®

 

764

 

1,001

 

1,813

 

3,018

Ximino®

(199)

1,773

567

3,775

Luxamend®

21

21

Total product revenues

$

15,279

$

16,043

$

44,405

$

55,074

Schedule of other revenue

Three-Month Periods Ended September 30,

 

Nine-Month Periods Ended September 30,

($ in thousands)

    

2023

    

2022

    

2023

    

2022

Non-refundable upfront payment from Maruho

 

$

19,000

 

$

$

19,000

 

$

Net milestone payment from Maruho

2,500

Royalties on sales of Rapifort® Wipes 2.5%

260

73

519

129

Total other revenue

$

19,260

$

73

$

19,519

$

2,629